ADI-PEG 20 + pembrolizumab

ADI-PEG 20 + pembrolizumab is an investigational combination therapy being evaluated for advanced solid tumors. **ADI-PEG 20** is a pegylated recombinant form of arginine deiminase, designed to deplete extracellular arginine and induce cytotoxicity in arginine-auxotrophic cancers. It also modulates the tumor immune microenvironment, increasing T cell infiltration and potentially upregulating PD-L1 expression. **Pembrolizumab** is a monoclonal antibody checkpoint inhibitor that binds and blocks the programmed cell death protein 1 (PD-1) receptor on T cells, thereby potentiating antitumor T cell activity. The rationale for the combination is that arginine depletion can increase immunogenicity and sensitivity to PD-1 inhibition in tumors with low baseline immunogenicity[1][2][3]. Primary development has focused on advanced solid tumors, particularly those with low PD-L1 expression.

Brand names

Keytruda

Other names

pegylated arginine deiminase + pembrolizumab